Abbott Laboratories (ABT.US) saw a 5% increase in stock price on Friday, after a jury ruled that Abbott and Reckitt's subsidiary were not responsible in the premature infant formula powder risk litigation.

A jury in St. Louis, Missouri, ruled on Thursday that Abbott and Reckitt's subsidiary Mead Johnson were not responsible for a severe intestinal condition in a baby boy. The lawsuit accused the above companies of failing to warn hospitals' neonatal intensive care units that the special formula powder used could lead to necrotizing enterocolitis (NEC).